CN105324113B - 共同施用类固醇和唑来膦酸以预防和治疗骨关节炎 - Google Patents

共同施用类固醇和唑来膦酸以预防和治疗骨关节炎 Download PDF

Info

Publication number
CN105324113B
CN105324113B CN201480026349.0A CN201480026349A CN105324113B CN 105324113 B CN105324113 B CN 105324113B CN 201480026349 A CN201480026349 A CN 201480026349A CN 105324113 B CN105324113 B CN 105324113B
Authority
CN
China
Prior art keywords
zoledronic acid
purposes
steroids
osteoarthritis
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480026349.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105324113A (zh
Inventor
凯达·德赛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Voltarra Pharmaceuticals Inc
Original Assignee
Voltarra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voltarra Pharmaceuticals Inc filed Critical Voltarra Pharmaceuticals Inc
Publication of CN105324113A publication Critical patent/CN105324113A/zh
Application granted granted Critical
Publication of CN105324113B publication Critical patent/CN105324113B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480026349.0A 2013-03-08 2014-03-07 共同施用类固醇和唑来膦酸以预防和治疗骨关节炎 Active CN105324113B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/791,685 US9012432B2 (en) 2013-03-08 2013-03-08 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
US13/791,685 2013-03-08
PCT/US2014/022169 WO2014138712A1 (en) 2013-03-08 2014-03-07 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Publications (2)

Publication Number Publication Date
CN105324113A CN105324113A (zh) 2016-02-10
CN105324113B true CN105324113B (zh) 2018-07-03

Family

ID=51488530

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480026349.0A Active CN105324113B (zh) 2013-03-08 2014-03-07 共同施用类固醇和唑来膦酸以预防和治疗骨关节炎

Country Status (12)

Country Link
US (1) US9012432B2 (enExample)
EP (1) EP2964209B1 (enExample)
JP (2) JP6839491B2 (enExample)
KR (1) KR102253394B1 (enExample)
CN (1) CN105324113B (enExample)
AU (1) AU2014225373B2 (enExample)
BR (1) BR112015021503B1 (enExample)
CA (1) CA2941346C (enExample)
EA (1) EA032067B1 (enExample)
ES (1) ES2904365T3 (enExample)
MX (1) MX377447B (enExample)
WO (1) WO2014138712A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101897122B1 (ko) 2016-03-09 2018-09-10 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
US10913771B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
JP6573293B2 (ja) 2016-03-09 2019-09-11 カイン サイエンス シーオー., エルティーディー.KINE SCIENCES Co., Ltd. 炎症性疾患の予防または治療用ペプチド及びこの用途
WO2017155234A1 (ko) 2016-03-09 2017-09-14 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
US10913772B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
JP7127616B2 (ja) 2019-06-04 2022-08-30 横河電機株式会社 情報処理装置、アラーム管理システム、及びアラーム管理方法
WO2021163432A1 (en) * 2020-02-12 2021-08-19 Levolta Pharmaceuticals, Inc. Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
CN114028571B (zh) * 2021-11-18 2023-04-28 中国医学科学院基础医学研究所 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535152A (zh) * 2000-11-29 2004-10-06 ��˹��ŵ�� 二膦酸类化合物在治疗疼痛方面的应用
US20110263537A1 (en) * 2010-04-26 2011-10-27 Ketan Desai Co-administration of steroids and zoledronic acid to prevent and treat side effects from zoledronic acid infusion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE72816T1 (de) 1986-11-21 1992-03-15 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
JP4774179B2 (ja) * 1999-12-27 2011-09-14 帝國製薬株式会社 外用貼付剤
MXPA03011331A (es) * 2001-06-08 2004-12-06 Johnson & Johnson Tratamiento del dolor mediante el direccionamiento de canales se abren por un nucleotido ciclico, activado mediante hiperpolarizacion.
US20030195171A1 (en) * 2002-04-05 2003-10-16 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin D formulation
RU2326695C2 (ru) * 2003-09-19 2008-06-20 Пфайзер Продактс Инк. Фармацевтические композиции и способы, включающие комбинации 2-алкилиденовых производных 9-нор-витамина d и бисфосфоната
EP1758653A2 (en) * 2004-06-17 2007-03-07 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain
JP5240925B2 (ja) * 2005-05-25 2013-07-17 カロシン ファーマ， インコーポレイテッド 変形性関節症を処置するための方法および組成物
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20080076743A1 (en) * 2006-08-03 2008-03-27 Nitec Pharma Ag Delayed-Release Glucocorticoid treatment of Rheumatoid Disease
WO2010071866A2 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
US9186273B2 (en) * 2009-05-04 2015-11-17 Nuvo Research Inc. Methods of treating pains associated with neuroma, nerve entrapment, and other conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535152A (zh) * 2000-11-29 2004-10-06 ��˹��ŵ�� 二膦酸类化合物在治疗疼痛方面的应用
US20110263537A1 (en) * 2010-04-26 2011-10-27 Ketan Desai Co-administration of steroids and zoledronic acid to prevent and treat side effects from zoledronic acid infusion

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response;Jones A.等;《Ann Rheum Dis》;19961231;第55卷(第11期);第829-832页 *
Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial;Laslett L.L.等;《Ann Rheum Dis》;20121231;第71卷(第8期);第1322-1328页 *

Also Published As

Publication number Publication date
US9012432B2 (en) 2015-04-21
US20140256681A1 (en) 2014-09-11
BR112015021503A2 (pt) 2018-05-15
JP6839491B2 (ja) 2021-03-17
EA032067B1 (ru) 2019-04-30
BR112015021503B1 (pt) 2022-09-06
JP2016510765A (ja) 2016-04-11
CA2941346C (en) 2020-03-10
JP2019104762A (ja) 2019-06-27
AU2014225373B2 (en) 2018-07-05
EA201591638A1 (ru) 2016-02-29
CN105324113A (zh) 2016-02-10
ES2904365T3 (es) 2022-04-04
KR102253394B1 (ko) 2021-05-20
EP2964209A1 (en) 2016-01-13
KR20150125001A (ko) 2015-11-06
MX2015011671A (es) 2016-05-12
AU2014225373A1 (en) 2015-10-22
MX377447B (es) 2025-03-10
EP2964209A4 (en) 2016-08-03
CA2941346A1 (en) 2014-09-12
EP2964209B1 (en) 2021-10-27
WO2014138712A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
US9737553B2 (en) Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
CN105324113B (zh) 共同施用类固醇和唑来膦酸以预防和治疗骨关节炎
JP2021183650A (ja) 治療用組成物、組合せ物および使用の方法
Montgomery et al. Androgen receptor modulation optimized for response (ARMOR) phase I and II studies: galeterone for the treatment of castration-resistant prostate cancer
SK13512003A3 (sk) Použitie N-bisfosfonátu na prípravu liečiva na liečenie kostných metastáz spojených s karcinómom prostaty
JP2018087228A (ja) がんのためのグルフォスファミド組み合わせ療法
Scott et al. Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma
JP7574184B2 (ja) 悪性腫瘍の治療方法
CN104039326A (zh) 用于癌症治疗的酶抑制剂
WO2021163432A1 (en) Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
US20060217425A1 (en) Methods of treating cancer using PPAR-gamma antagonists
IT202100009926A1 (it) Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
US20250177352A1 (en) Combination treatment for cancer
JP2003238414A (ja) 医薬組成物
RU2816126C2 (ru) Способ лечения злокачественной опухоли
JP2016512836A (ja) ホジキンリンパ腫を治療するための４−シアノ−ｎ−（２−（４，４−ジメチルシクロヘキサ−１−エン−１−イル）−６−（２，２，６，６−テトラメチルテトラヒドロ−２ｈ−ピラン−４−イル）ピリジン−３−イル）−１ｈ−イミダゾール−２−カルボキサミド
US20240058349A1 (en) Pi3k inhibitors for protection against glucocorticoid-induced atrophy
Berdelou et al. Radioiodine Refractory Thyroid Cancer
BR112017028519B1 (pt) Uso de defactinibe na preparação de um medicamento para tratamento de câncer
JPH1149673A (ja) ガン特効薬
TW201212911A (en) Use of teriflunomide for treating Multiple Sclerosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant